Literature DB >> 8695252

Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation.

J Pihkala1, U M Saarinen, U Lundström, K Virtanen, K Virkola, M A Siimes, E Pesonen.   

Abstract

Cardiotoxicity is a potential adverse effect of anthracycline (A) therapy. Radiotherapy (XRT) may also cause a variety of cardiac complications. The purpose of the present study was to evaluate these cardiac side-effects in children and adolescents treated for cancer. We assessed the cardiac status of 91 patients, divided into three groups: Group A (n = 53) had anthracyclines at a mean cumulative dose of 410 mg/m2, group A+XRT (n = 26) had both chest irradiation (XRT) and A (mean 360 mg/m2), and group XRT (n = 12) had XRT alone. The patients differed from the controls in both systolic and diastolic indices of myocardial function. In echocardiography, the left ventricular (LV) contractility was abnormal in 32% in group A, in 50% in group A+XRT, and in 8% in group XRT. In radionuclide cineangiography, the LV ejection fraction was subnormal in 19% in group A, in 24% in group A+XRT, and in 1 patient in group XRT. A higher cumulative dose of A predicted decreased contractility. Treatment with A and/or XRT often leads to cardiotoxicity. Although in most cases this cardiotoxicity seems to be mild and subclinical, the long-term clinical sequelae merit further evaluation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8695252     DOI: 10.1016/0959-8049(95)00555-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

Review 1.  Cardiotoxicity of doxorubicin and other anthracycline derivatives.

Authors:  D Jain
Journal:  J Nucl Cardiol       Date:  2000 Jan-Feb       Impact factor: 5.952

Review 2.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

Review 3.  Cardiotoxicity of cancer chemotherapy: implications for children.

Authors:  Valeriano C Simbre; Sarah A Duffy; Gul H Dadlani; Tracie L Miller; Steven E Lipshultz
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 4.  New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin.

Authors:  Iain Rj Macpherson; Tr Jeffry Evans
Journal:  Breast Cancer (Dove Med Press)       Date:  2009-08-31

5.  [Late effects after chemotherapy].

Authors:  W Pönisch; D Niederwieser
Journal:  Internist (Berl)       Date:  2006-03       Impact factor: 0.743

6.  Cardiomyopathy Caused by Antineoplastic Therapies.

Authors:  Valeriano C. Simbre II; M. Jacob Adams; Sampada S. Deshpande; Sarah A. Duffy; Tracie L. Miller; Steven E. Lipshultz
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-12

7.  Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma.

Authors:  David J Cutter; Johanna Ramroth; Patricia Diez; Andy Buckle; Georgios Ntentas; Bilyana Popova; Laura Clifton-Hadley; Peter J Hoskin; Sarah C Darby; John Radford; Tim Illidge
Journal:  J Clin Oncol       Date:  2021-08-13       Impact factor: 50.717

8.  Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer.

Authors:  K Towns; P L Bedard; S Verma
Journal:  Curr Oncol       Date:  2008-01       Impact factor: 3.677

9.  Cardiac damage after treatment of childhood cancer: a long-term follow-up.

Authors:  Veronika Velensek; Uros Mazic; Ciril Krzisnik; Damjan Demsar; Janez Jazbec; Berta Jereb
Journal:  BMC Cancer       Date:  2008-05-20       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.